FINDING OF A PROHIBITED SUBSTANCE - FLUNIXIN

The National Horseracing Authority of Southern Africa (NHA) confirms a Prohibited Substance finding arising from routine post-race specimen collection.

The presence of Flunixin, a non-steroidal anti-inflammatory drug (NSAID) classified as a Class 4 prohibited substance, was disclosed following analysis of a specimen collected from OKAVANGO after the running of Race 5 at Hollywoodbets Kenilworth Racecourse on 10 January 2026.

Flunixin meglumine is widely used in equine veterinary practice for the relief of pain, reduction of inflammation, and control of fever. It is commonly prescribed for conditions such as musculoskeletal injury, colic, or post-operative recovery. While safe and effective when used under veterinary supervision, its administration is prohibited within defined withdrawal periods prior to racing and must be accurately recorded in the Veterinary Treatment Register (VTR).

Following notification of the analytical finding, the Trainer, Mr S J Snaith conducted an internal investigation. This included review of the stable and race-day video footage as well as a detailed examination of the VTR. Through this process, the Trainer was able to conclusively establish the circumstances that led to the positive finding. The NHA notes and commends this proactive and transparent approach.

Mr S J Snaith elected to sign an Admission of Guilt for a contravention of Rule 73.2.4, and the penalty of a fine of R25 000 was imposed.

In determining the penalty, due consideration was given to the classification of substance, the Trainer’s clean penalty record in respect of prior prohibited substance contraventions over the preceding five-year period, the concentration detected in the specimen, and the status of the race.

In accordance with Rule 72.3.2, OKAVANGO is disqualified from the race.

NHA release

Note that I Salute You so now declared the winner of the G2 Premier Trophy and Oisin Murphy is no longer the winning jockey. Peter Muscutt is now the winning trainer of that event.